Dr. Ross Mason
Associate Professor
Phone: 902-425-3940
Fax: 902-422-0033
Mailing Address:
- Prostate cancer
- Bladder cancer
- Kidney cancer
- Testis cancer
- Penile cancer
- General Urology
- Epidemiology
- Clinical Outcomes Research
Recent Publications
Pubmed
Lawen, T., Ilie, G., Mason, R., Rendon, R., Spooner, J., Champion, E., ... & Rutledge, R. D. H. (2024). Six-Month Prostate Cancer Empowerment Program (PC-PEP) Improves Urinary Function: A Randomized Trial. Cancers, 16(5), 958.
MacDonald, L., Rendon, R. A., Thana, M., Wood, L., MacFarlane, R., Bell, D., ... & Mason, R. (2024). An in-depth analysis on the effects of body composition in patients receiving neoadjuvant chemotherapy for urothelial cell carcinoma. Canadian Urological Association Journal, 18(6).
Gillis, C. J., Sherazi, A., Rendon, R. A., Ilie, G., & Mason, R. (2024). Examining the utility of routine perioperative hemoglobin monitoring in patients undergoing radical nephrectomy. Canadian Urological Association Journal, 18(6).
Education
- BSc (St. Francis Xavier University)
- MD (Dalhousie University)
- Urology residency (Dalhousie University)
- Fellowship in Urologic Oncology (Mayo Clinic)
- Masters of Science in Clinical and Transllational Science (Mayo Clinic)
Designations
- FRCSC
- Director of resident research (Department of Urology, Dalhousie University)
Dr. Ross Mason completed a Bachelor of Science in Chemistry (first class honors) before attending Dalhousie University for Medical School and a residency in Urology. He subsequently completed a Society of Urologic Oncology accredited fellowship in Urologic Oncology at the Mayo Clinic in Rochester, Minnesota where he also completed a Master's Degree in Clinical and Translational science. His clinical and research interests include all aspects of urologic oncology with a particular focus on malignancies of the kidney, prostate, and bladder.